According to the Guidelines of the WHO and the International Commitee of Medical Journal Editors (ICMJE), a new trial registry was realized.
Clinical Trials Registry
In 2004, the members of the International Committee of Medical Journal Editors (ICMJE) published a joint editorial in close cooperation with the World Health Organization (WHO), to promote registration of clinical trials. Main purpose was, to provide a comprehensive, publicly available database of clinical trials. (http://www.icmje.org )
The members of the ICMJE (International committee of medical journal editors, formerly known as Vancouver group) are major journals or librarys outside europe, including the skandinavian countries. In addition, a large number of non-member journals are following the ICMJE’s guidelines.
The WHO supported the development of a clinical trial register to ensure transparency, to increase public trust in the conduct of clinical research as well as to make results available to the public. For this purpose, a Metaregister - the International Clinical Trial Registry Platform (ICTRP) - was established in august 2005 (http://www.who.int/ictrp/en/). With this approach, the WHO has no plans to administer its own register. Trialists should rather continue to register with existing registers.
Due to the ICMJE guidelines, the existing German Leukemia Trial Registry is actually worked over to meet additional technical requirements to become a member register of the WHO. Major topics are the assignment of a UTRN (Universal Trial Reference Number) and some fields of the “minimal-data-set” which contains key information for every registered study must be completed. The Minimal-Data-Set will afterwards be uploaded from the national registry to the WHO-Metaregister. This procedure, avoids double-registration in more than one register.
The new Registry is bilingual (german/english), and provides short-protocols of ongoing german and european Leukemia Trials.
Template for Short-Protocols
Template
(194KB)